Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China
在中国，2022年末至2023年初的COVID-19疫情期间，人源单克隆抗体F61鼻喷雾剂有效保护了高危人群免受SARS-CoV-2变异株的感染。
期刊:Emerging Microbes & Infections
影响因子:7.5
doi:10.1080/22221751.2023.2284297
Liu, Ying; Zhang, Jiayou; Liu, Wen; Pan, Yongbing; Ruan, Shunan; Nian, Xuanxuan; Chen, Wei; Sun, Lina; Yin, Qiangling; Yue, Xin; Li, Qingliang; Gui, Fang; Wu, Cong; Wang, Shuzhen; Yang, Yunkai; Jing, Zhaofei; Long, Feiguang; Wang, Zejun; Zhang, Zeyu; Huang, Chaolin; Duan, Kai; Liang, Mifang; Yang, Xiaoming
单克隆抗体
Human
炎症/感染
SARS-CoV-2
